Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Sells 2,000 Shares
SEC Form 4 Filing
Chief Medical Officer of Gilead Sciences, Merdad Parsey, sold 2,000 shares of common stock at a price of $83.83 per share on October 1, 2024, according to a Form 4 filing with the SEC.
Summary
- On October 1, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, sold 2,000 shares of the company's common stock.
- The sale was executed at a price of $83.83 per share.
- Following the transaction, Parsey directly owns 100,189 shares of Gilead Sciences' common stock.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 9, 2023.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. They can be for personal financial planning or diversification. The use of a pre-arranged Rule 10b5-1 trading plan suggests the sale was planned in advance and not based on any inside information.
Stakeholder Impact
- The stock sale by a high-ranking executive could potentially cause short-term uncertainty among shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| November 9, 2023 | Date of adoption of the Rule 10b5-1 trading plan. |
| October 1, 2024 | Date of the stock sale transaction. |
| October 2, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.